Poly Medicure Navigates Growth Amidst Strategic Transformation and Market Headwinds

Poly Medicure Limited, a prominent player in the Indian medical devices sector, has reported a robust performance for the third quarter and nine months ended December 31, 2025 (Q3 & 9M FY26). The company's consolidated revenue from operations for Q3 FY26 stood at INR 493.7 crore, marking a significant 16.4% year-on-year growth. For the nine-month period, consolidated revenue reached INR 1,340.7 crore, up 9.1% from the previous year. While the company demonstrates strong strategic execution and innovation, it is also actively navigating market headwinds, including intense competition and regulatory shifts.

The quarter's financial narrative highlights Poly Medicure's strategic pivot towards high-complexity, high-growth segments. This transition is evident in its expanding product portfolio and enhanced market reach, particularly through recent acquisitions. Despite a slight dip in Profit After Tax (PAT) for Q3 FY26 to INR 70.8 crore, primarily due to one-time extraordinary expenses related to the Revised Labour Code and acquisition costs, the underlying operational performance remains strong. Consolidated Operating EBITDA for Q3 FY26 grew by 2.8% to INR 119.4 crore, with a margin of 24.2%.

Strategic Evolution and Market Expansion

Poly Medicure is undergoing a fundamental upgrade of its business model, moving beyond low-technology products to focus on high-growth areas such as cardiology, critical care, and orthopedics. This strategic shift is bolstered by successful inorganic growth initiatives. The acquisitions of PendraCare Group, specializing in cardiology, and Citieffe Group, focused on orthopedics, are pivotal to this transformation. These acquisitions not only expand Poly Medicure's product offerings but also provide a 'Made in Europe' advantage, access to high-end technologies, and faster regulatory approvals, particularly within European markets. The integration process for these entities is well underway, with management anticipating significant synergies and a full-year impact visible in FY27.

Innovation remains a cornerstone of Poly Medicure's strategy. The company recently secured full regulatory approval from the DCGI for two groundbreaking, in-house developed products: the Intravenous Lithotripsy System (IVL) and Drug Eluting Balloon (DEB). These high-end medical devices, with average selling prices exceeding INR 1,15,000, are set to address complex cardiovascular conditions in India and are expected to be commercialized soon. In 9M FY26, Poly Medicure launched 19 new products, underscoring its commitment to continuous innovation and its robust R&D platform, which boasts 394 patents.

To support its ambitious growth trajectory, Poly Medicure invested INR 234 crore in capital expenditure during 9M FY26. These investments are directed towards establishing new manufacturing facilities in Mitrol and Haridwar, expanding existing capacities, and acquiring additional land at the YEIDA Medical Devices Park near Noida. These new plants are projected to be fully operational within the next 18 to 24 months, ensuring future scale and operational efficiency.

Financial Performance Summary

Navigating Market Dynamics and Future Outlook

While Poly Medicure's strategic initiatives are strong, the company faces notable market challenges. Aggressive dumping by Chinese manufacturers, particularly in export markets, has created significant pricing pressure and impacted standalone revenue growth. The company is actively engaging with the government to advocate for anti-dumping measures to protect the domestic medical device industry. Furthermore, the transition to new regulatory systems in Europe, such as the MDD to MDR shift, has led to initial product drops and delays in approvals, affecting European business growth.

Despite these headwinds, Poly Medicure's domestic private market business has shown robust growth of 22.5%, and the company is deliberately reducing its exposure to lower-margin government business, which often entails payment delays. The company's strong liquidity position, with INR 839.8 crore as of December 31, 2025, provides a solid foundation to fund its ambitious organic and inorganic growth strategies. Management's forward-looking guidance projects consolidated revenue for H2 FY26 to be approximately 20% higher than H1 FY26. For the next financial year, domestic business is expected to grow around 25%, and export business between 12% and 15%, leading to an overall total business growth of 20%, with operating profit growing at a similar rate. The company also aims to increase its dialysis market share from the current 10% to 15-17% over the next 2-3 years.

Segmental Performance (Q3 FY26)

Poly Medicure's Q3 and 9M FY26 performance underscores a period of strategic transformation and disciplined execution. By focusing on high-growth segments, leveraging acquisitions, and investing in R&D and capacity expansion, the company is positioning itself for sustained long-term growth. While external market pressures persist, management's proactive approach to market realities and commitment to innovation provide a clear pathway for future value creation.